A Phase 2 interventional study of Panitumumab and Bevacizumab in Colon Cancer, Colorectal Cancer and Rectal Cancer, sponsored by Amgen. Completed at 95 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-06.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing panitumumab in Colonic Neoplasms — 1 open to participants now, 2 under way, 1 of them phase 3. Panitumumab · Colonic Neoplasms.
Among the 22 studies testing panitumumab in Colonic Neoplasms, this one is the 6th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2009, is one of 15 in phase 2, and was the 11th registered.
2,456 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
Browse Colonic Neoplasms studies →1 of the 22 studies testing panitumumab in Colonic Neoplasms is open now, in 3 countries. Recruiting first, the newest first:
IFOM ETS - The AIRC Institute of Molecular Oncology · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 327 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 71 (22%) stop at 75 or younger; 19 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 5
First in 2000; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 285 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 116 across the 21 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 22 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
15 studies in Colonic Neoplasms by Amgen: none open now, none under way, none of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 15 studies in Colonic Neoplasms by Amgen, this one is the 3rd largest by enrollment, is one of 3 that started in 2009, is one of 9 in phase 2, and was the 12th registered.
Amgen’s Colonic Neoplasms studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing panitumumab in Colonic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 15 in Colonic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU) (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Drug: Panitumumab · Drug: mFOLFOX6
Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Drug: Bevacizumab · Drug: mFOLFOX6
Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
Also known as: Vectibix
Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
Also known as: Avastin
mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Overall Survival
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Percentage of Participants With an Objective Response
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Duration of Response
For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Time to Disease Progression
Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Time to Initial Objective Response
For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Resection Rate
The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Overall Survival in Participants With Wild-type RAS
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Overall Survival in Participants With Wild-type RAS / BRAF
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Percentage of Participants With an Objective Response for Participants With Wild-type RAS
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.
Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Number of Participants With Adverse Events (AEs)
Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug.
Time frame: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.
First patient was enrolled on 24 April 2009; last patient was enrolled on 09 December 2011.
| Milestone | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Started | 142 | 143 |
| Received study treatment | 139 | 139 |
| Completed | 114 | 122 |
| Not completed | 28 | 21 |
| Withdrew: Did not receive study drug | 3 | 4 |
| Withdrew: Still in treatment | 25 | 17 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Progression-free Survival (PFS) | 10.9 (9.4 to 13.0) | 10.1 (9.0 to 12.6) |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Overall Survival | NA (28.8 to NA) | 25.4 (22.9 to 29.5) |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.
| percentage of participants | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Percentage of Participants With an Objective Response | 57.75 (49.18 to 65.98) | 53.52 (44.97 to 61.93) |
For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Duration of Response | 10.0 (8.4 to 12.9) | 9.0 (7.4 to 9.5) |
Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Time to Disease Progression | 11.0 (9.7 to 13.1) | 11.1 (9.3 to 12.7) |
For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Time to Initial Objective Response | 1.8 (1.7 to 2.3) | 1.9 (1.7 to 3.7) |
The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.
| percentage of participants | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Resection Rate | 12.68 (7.69 to 19.29) | 11.19 (6.53 to 17.53) |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS) | 13.0 (10.9 to 15.1) | 9.5 (9.0 to 12.7) |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | 13.1 (10.9 to 15.8) | 9.7 (7.9 to 12.7) |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Overall Survival in Participants With Wild-type RAS | NA (28.8 to NA) | 29.0 (24.3 to NA) |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.
| months | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Overall Survival in Participants With Wild-type RAS / BRAF | NA (NA to NA) | 29.0 (24.3 to NA) |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.
| percentage of participants | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Percentage of Participants With an Objective Response for Participants With Wild-type RAS | 63.64 (52.69 to 73.63) | 60.49 (49.01 to 71.19) |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.
| percentage of participants | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF | 63.64 (51.88 to 74.30) | 61.54 (49.83 to 72.34) |
Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug.
| participants | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| Any adverse event (AE) | 139 | 139 |
| AE with worst grade of 3 | 88 | 78 |
| AE with worst grade of 4 | 31 | 28 |
| AE with worst grade of 5 | 7 | 9 |
| Serious adverse event (SAE) | 61 | 53 |
| AE leading to discontinuation of study drug | 34 | 37 |
| Any treatment-related adverse event (TRAE) | 138 | 136 |
| Treatment-related AE with worst grade of 3 | 92 | 77 |
| Treatment-related AE with worst grade of 4 | 24 | 25 |
| Treatment-related AE with worst grade of 5 | 3 | 2 |
| Serious treatment-related adverse event | 37 | 28 |
| TRAE leading to discontinuation of study drug | 28 | 29 |
Collected over The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus mFOLFOX6 | — | 61/139 (43.9%) | 139/139 (100%) |
| Bevacizumab Plus mFOLFOX6 | — | 53/139 (38.1%) | 139/139 (100%) |
| Event | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/139 | 1/139 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/139 | 6/139 |
| PyrexiaGeneral disorders | 2/139 | 4/139 |
| SyncopeNervous system disorders | 0/139 | 4/139 |
| Deep vein thrombosisVascular disorders | 4/139 | 4/139 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/139 | 3/139 |
| IleusGastrointestinal disorders | 1/139 | 3/139 |
| PneumoniaInfections and infestations | 2/139 | 3/139 |
| SepsisInfections and infestations | 3/139 | 2/139 |
| DehydrationMetabolism and nutrition disorders | 3/139 | 0/139 |
| Event | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 86/139 | 9/139 |
| DiarrhoeaGastrointestinal disorders | 84/139 | 84/139 |
| NauseaGastrointestinal disorders | 75/139 | 83/139 |
| NeutropeniaBlood and lymphatic system disorders | 63/139 | 66/139 |
| FatigueGeneral disorders | 50/139 | 65/139 |
| HypomagnesaemiaMetabolism and nutrition disorders | 57/139 | 9/139 |
| Decreased appetiteMetabolism and nutrition disorders | 56/139 | 44/139 |
| Dry skinSkin and subcutaneous tissue disorders | 53/139 | 12/139 |
| AstheniaGeneral disorders | 50/139 | 44/139 |
| Mucosal inflammationGeneral disorders | 49/139 | 21/139 |
| Age, Continuous(years) | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 | Total |
|---|---|---|---|
| Mean | 61.6 ± 10.4 | 60.5 ± 9.8 | 61.0 ± 10.1 |
| Sex: Female, Male(Participants) | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 | Total |
|---|---|---|---|
| Female | 56 | 47 | 103 |
| Male | 86 | 96 | 182 |
| Race/Ethnicity, Customized(participants) | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 | Total |
|---|---|---|---|
| White or Caucasian | 131 | 127 | 258 |
| Black or African American | 9 | 6 | 15 |
| Hispanic or Latino | 2 | 5 | 7 |
| Asian | 0 | 4 | 4 |
| Japanese | 0 | 1 | 1 |
| Prior Adjuvant Oxaliplatin Therapy(participants) | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 | Total |
|---|---|---|---|
| Yes | 14 | 14 | 28 |
| No | 128 | 129 | 257 |
| RAS and BRAF Mutation Status(participants) | Panitumumab Plus mFOLFOX6 | Bevacizumab Plus mFOLFOX6 | Total |
|---|---|---|---|
| BRAF wild-type | 103 | 108 | 211 |
| RAS Wild-type | 88 | 82 | 170 |
| RAS/BRAF wild-type | 77 | 79 | 156 |
| Testing not performed | 13 | 18 | 31 |
| Sample acceptance failure | 8 | 7 | 15 |
Ran from Apr 2009 to primary completion in May 2012, 37 months.
Results were first posted in Aug 2014, 2 years 2 months after primary completion.
Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 37 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab